

January 22, 2016



Ligand to Report Fourth Quarter and Full Year 2015 Results on February 10th

SAN DIEGO-- **Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)** announced today plans to report fourth quarter and full year 2015 financial results on February 10, 2016. Ligand's CEO John Higgins, President and COO Matt Foehr and CFO Matt Korenberg will host the conference call.

Fourth Quarter and Full Year 2015 Earnings Call

What: Ligand conference call to discuss financial results and provide general business updates

When: Wednesday, February 10, 2016

Time: 1:30 p.m. Pacific time (4:30 p.m. Eastern time)

Conference Call: (877) 407-4019 within the U.S.
(201) 689-8337 outside the U.S.
Passcode: Ligand

Replay: (877) 660-6853 within the U.S.
(201) 612-7415 outside the U.S.
Passcode: 13628528

About Ligand Pharmaceuticals

Ligand is a biopharmaceutical company with a business model focused on developing or acquiring royalty generating assets and coupling them with a lean corporate cost structure. Ligand's goal is to produce a bottom line that supports a sustainably profitable business. By diversifying the portfolio of assets across numerous technology types, therapeutic areas, drug targets and industry partners, we offer investors an opportunity to invest in the increasingly complicated and unpredictable pharmaceutical industry. In comparison to its peers, we believe Ligand has assembled one of the largest and most diversified asset portfolios in the industry with the potential to generate revenue in the future. These therapies seek to address the unmet medical needs of patients for a broad spectrum of diseases including thrombocytopenia, multiple myeloma, hepatitis, ventricular fibrillation, muscle wasting, Alzheimer's disease, dyslipidemia, diabetes, anemia, asthma, focal segmental glomerulosclerosis, menopausal symptoms and osteoporosis. Ligand's Captisol® platform technology is a patent-protected, chemically modified cyclodextrin with a structure designed

to optimize the solubility and stability of drugs. OmniAb[®] is a patent-protected transgenic animal platform used in the discovery of fully human mono- and bispecific therapeutic antibodies. Ligand has established multiple alliances, licenses and other business relationships with the world's leading pharmaceutical companies including Novartis, Amgen, Merck, Pfizer, Celgene, Gilead, Janssen, Baxter International and Eli Lilly.

Follow Ligand on Twitter @Ligand_LGND.

View source version on businesswire.com:

<http://www.businesswire.com/news/home/20160122005209/en/>

Ligand Pharmaceuticals Incorporated

Todd Pettingill

investors@ligand.com

(858) 550-7500

or

LHA

Bruce Voss

bvoss@lhai.com

(310) 691-7100

Source: Ligand Pharmaceuticals Incorporated